AgingResearch.NewsJoin free

Phase 1Completed

A Study of Modified mRNA Vaccines in Healthy Adults

Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults

Sponsor
ModernaTX, Inc. (Industry)
Enrollment
308 enrolled
Conditions
SARS-CoV-2; Seasonal Influenza; Respiratory Syncytial Virus; Cytomegalovirus
Interventions
mRNA-1273; mRNA-1010; mRNA-1345; FLUAD®; mRNA-1647
Ages
adults, older adults
Registry
NCT05397223

Full record on ClinicalTrials.gov

From the registry

The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.

Primary outcomes

  • Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
  • Number of Participants With Unsolicited Adverse Events (AEs)
  • Number of Participants With Serious AEs (SAEs), AEs of Special Interest (AESIs), and AEs Leading to Study Withdrawal or Discontinuation of Study Vaccination
  • Number of Participants with Medically Attended Adverse Events (MAAEs)

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started